Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

Grávalos, C.; Sanmartín, O.; Gúrpide, A.; España, Agustín; Majem, Margarita; Suh Oh, H.J.; Aragón, I.; Segura Tigell, Sonia; Beato, Carmen; Botella, R.

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Grávalos, C.
dc.contributor.author Sanmartín, O.
dc.contributor.author Gúrpide, A.
dc.contributor.author España, Agustín
dc.contributor.author Majem, Margarita
dc.contributor.author Suh Oh, H.J.
dc.contributor.author Aragón, I.
dc.contributor.author Segura Tigell, Sonia
dc.contributor.author Beato, Carmen
dc.contributor.author Botella, R.
dc.date.accessioned 2019-07-03T06:35:03Z
dc.date.issued 2019
dc.description.abstract Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management.
dc.format.mimetype application/pdf
dc.identifier.citation Grávalos C, Sanmartín O, Gúrpide A, España A, Majem M, Suh Oh HJ. Et al. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2019 May;21(5):556-571. DOI: 10.1007/s12094-018-1953-x
dc.identifier.doi http://dx.doi.org/10.1007/s12094-018-1953-x
dc.identifier.issn 1699-048X
dc.identifier.uri http://hdl.handle.net/10230/41915
dc.language.iso eng
dc.publisher Springer
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.subject.keyword Anti-EGFR
dc.subject.keyword Antiangiogenic drugs
dc.subject.keyword Dermatological toxicity
dc.subject.keyword Immune checkpoint inhibitors
dc.subject.keyword MTOR inhibitors
dc.subject.keyword Targeted therapies
dc.title Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/acceptedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)